Apatorsen + Carboplatin + Pemetrexed

This is a combination therapy that was evaluated in a randomized, double-blinded, phase II clinical trial for patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). The combination includes apatorsen (an antisense oligonucleotide targeting heat shock protein 27 mRNA), carboplatin (a platinum-based chemotherapy drug), and pemetrexed (an antifolate antineoplastic agent). Apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27), which increases with cancer treatment and with tumor stage and grade. High levels of Hsp27 contribute to cancer cell survival, proliferation, and migration, and also play a role in dampening a cancer patient's immune function. By targeting Hsp27, apatorsen aims to disable cancer cells' defenses and overcome treatment resistance. Carboplatin and pemetrexed are established chemotherapy drugs used in combination for treating non-small cell lung cancer. Pemetrexed is a pyrimidine-based folate analog that suppresses tumor growth by inhibiting both DNA synthesis and folate metabolism at multiple target enzymes. Carboplatin is a platinum-based chemotherapy that destroys quickly dividing cells, such as cancer cells. The phase II trial (known as the Spruce trial) evaluated the efficacy of adding apatorsen to the standard carboplatin/pemetrexed regimen in patients with previously untreated metastatic nonsquamous NSCLC. Approximately 155 patients were randomized to receive either apatorsen or placebo in combination with carboplatin and pemetrexed. The primary endpoint of the study was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate, and toxicity. The trial concluded that while the addition of apatorsen to carboplatin and pemetrexed was well tolerated, it did not improve outcomes in patients with metastatic nonsquamous NSCLC in the first-line setting. This combination therapy represents an attempt to improve standard chemotherapy by targeting treatment resistance mechanisms, specifically through the inhibition of Hsp27 production.